New Oral Drug Delivery Partnership Gives Wider Access to IntelliCap Technology
News Nov 01, 2014
Medimetrics has established a partnership with pharmaceutical services business, Scintipharma, to deliver wider access to its technology. Both companies are exhibiting at this year’s American Association of Pharmaceutical Scientists (AAPS) congress in Chicago, USA, 2-6 November 2014.
IntelliCap is an extremely powerful and comprehensive tool for the early-stage development of new drugs or for the life cycle management of existing drugs. Its use in drug trials enables researchers to conduct advanced site absorption studies in the gastro-intestinal (GI) tract, which deliver more complete and robust results on the merits and properties of the drug product. The outcome is a more cost-efficient product development programme.
As chief executive officer Dr Olaf Weiner explained: “Patients prefer to take drugs orally, so manufacturers need to understand exactly how a drug formulation performs as it delivers its dosage at various points in the GI tract. IntelliCap has a significant role to play in helping direct future investment by providing speedy validation of a compound’s suitability for moving towards approval, or indicating its limitations.
“Combining IntelliCap’s unique properties with the established expertise of Scintipharma, we can provide expanded access to services that directly benefit the customer. This will further accelerate the formulation development process and provide early identification of those products most likely to succeed.”
Scintipharma, based in Kentucky, USA, was founded more than 22 years ago by scientists Walter Doll and Erik Sandefer. As Dr Doll commented: “Our mission has always been to help improve the early drug development process so that companies can optimize the efficiency of a new formulation, or avoid spending time and resources on products with little chance of success.
“The partnership with Medimetrics builds on our existing strengths of outstanding service and offering innovative products. The opportunity to include the IntelliCap products expands the choice and breadth of services available to customers.”
Medimetrics offers two IntelliCap systems: IntelliCap CR (controlled release), for the targeted delivery of drugs with any programmed delivery profile; and the new IntelliCap FR (fast release), for the targeted delivery of any type of drug payload, including solids and powders. The technology’s unique properties also include continuous real-time measurement and reporting of the pH conditions within the GI tract.
Novel Chemistry Technique Simplifies Late-Stage Modification of Drug CompoundsNews
Chemists at The Scripps Research Institute (TSRI) have invented a technique that overcomes a long-standing problem in organic chemistry and should streamline the process of discovery and development for many new drugs.READ MORE
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE